Novo Nordisk and partner dose first patient in clinical heart failure study

After more than a year’s delay, the Danish pharma company rolls out a phase 1/2 clinical study along with Japanese partner Heartseed designed to restore cardiac functions for patients suffering advanced heart failure.

by marketwire, translated by simon øst vejbæk

Novo Nordisk and partner Tokyo-based Heartseed announce first patient dose in a new cell therapy study.

The clinical study will enroll a total of ten patients and spans for 52 weeks, informs Novo Nordisk in a press release Friday.

Heartseed and Novo Nordisk first publicly announced their global collaboration back in 2021, when Novo Nordisk gained exclusive rights to develop, produce and commercialize HS-001 worldwide except in Japan.

At the time, the clinical phase 1/2 study was slated for the latter half of 2021, meaning the overall delay amounts to slightly more than a year.

HS-001 is an investigational cell therapy consisting of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSC) designed by Heartseed to restore heart muscle and functions in patients with advanced heart failure.

New partnership may pave the way for first Novo Nordisk stem cell treatment
For subscribers
Novo Nordisk enters agreement with Fujifilm Cellular Dynamics
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers

Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers
Country Manager: Indians will have to wait for Wegovy until 2026
Up to 40% of the female population aged 30-49 in India is overweight.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Foto: Genmab / PR

Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers

Pharma & biotech

2seventy narrows focus and lays off 40% of its workforce

US-based 2seventy bio, which is working with Novo Nordisk on a hemophilia drug, will lay off 176 employees and focus on growth of approved cancer drug.

For subscribers

The approval in Japan is based on two phase I/II studies with Epkinly. | Foto: Uncredited/AP/Ritzau Scanpix

Pharma & biotech

Japanese authorities approve cancer drug by Genmab and Abbvie

The drug was launched in the US at the end of the second quarter and has also received a positive recommendation from the regulatory authorities in Europe.

For subscribers